Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast ...
Dec 3, 2015
0
0